Navigation Links
New sickle cell anemia therapy advances to Phase II clinical trials
Date:6/12/2013

sed in patients too ill to undergo exercise stress testing using a treadmill. It is given in brief (10 seconds), intravenous doses.

In Phase I of the trial, a dose escalation safety study, participants received very low doses of Lexiscan administered by continuous intravenous infusion, over 12 or 24 hours, to suppress inflammation. Following this initial study of adults with sickle cell anemia not experiencing pain crises, Phase II of the trial will expand to include patients experiencing pain crises and acute chest syndrome, and children over 14. Dr. Linden adds that Phase II will be a placebo-controlled trial.


'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial?
2. Potential gene therapy approach to sickle cell disease highlighted at ASH
3. Nature study reveals loss of essential blood cell gene leads to anemia
4. Why a hereditary anemia is caused by genetic mutation in mechanically sensitive ion channel
5. Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
6. Discovery may help prevent chemotherapy-induced anemia
7. Scientists identify potential drug target for treatment-resistant anemias
8. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
9. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
10. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
11. The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)...  Through a well-rounded UAS delegation representing private industry, government, ... showing at AUVSI,s Unmanned 2015 conference last week in ... UAS industry met with over 200 hundred people ... the UAS ecosystem. "Our message is clear ... Aerospace Rich Knoll . "If you want to fly ...
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... Science Program Organization (HFSPO) is awarding $34 million to ... the HFSP Research Grants. Applicants went through a rigorous ... with 715 submitted letters of intent. This year, 10 ... with 23 Program Grants (involving 81 scientists). Each team ...
... monkeys learn to associate a picture with a reward, ... activity in the monkeys, visual cortex. This finding was ... Leuven and Harvard Medical School) and American colleagues using ... leading journal Neuron . Our visual perception ...
... Science Program Organization (HFSPO) is pleased to announce the ... for 2013 following a rigorous selection process in a ... in this round from applicants originating from 61 different ... scientists within 3 years of the Ph.D. degree who ...
Cached Biology News:Impressive list of research teams for the 2013 HFSP Research Grants 2Reward linked to image is enough to activate brain's visual cortex 2The 2013 HFSP postdoctoral fellowship awards 2
(Date:5/20/2015)... FRANCISCO, Calif. , May 20, 2015 /PRNewswire/ ... ) today presented preliminary data demonstrating the ability ... idiopathic pulmonary fibrosis (IPF) from other interstitial lung ... findings suggest the classifier,s potential to help thousands ... to resolve ambiguity in IPF diagnosis – a ...
(Date:5/20/2015)... 20, 2015  Select Medical Corporation ("Select") (NYSE: ... Commission granted early termination of the waiting period ... 1976, as amended, applicable to the acquisition of ... joint venture that Select has created with Welsh, ... previously announced, MJ Acquisition Corporation has signed a ...
(Date:5/20/2015)... 20, 2015  Marc Tessier-Lavigne, president of The ... $100 million from The Marie-Josée and Henry R. ... building that will be the centerpiece of the ... Henry R. Kravis Research Building, two stories high, ... approximately three city blocks following the shoreline of ...
(Date:5/20/2015)... May 19, 2015 Research and Markets ... of the "Bone Morphogenetic Proteins Market (Types ... Reconstructive and Oral - Maxillofacial) - Global Industry ... - 2022" report to their offering. ... studied based on the types of recombinant BMPs, ...
Breaking Biology Technology:Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2
... , , SINGAPORE , ... the article entitled "Neuroprotective and,Neuroproliferative Activities of NeuroAiD", reporting pharmacological ... as well as its effectiveness in neurological functions recovery. , ... by Prof. Michel Lazdunski , world-renowned,specialist of pharmacology. , ...
... ... learn how Microsoft® products, such as SharePoint and Office 2007, can be configured to model ... provide a cost-effective FDA regulated Quality System. , ... Bedford, MA (PRWEB) February 11, 2010 -- Business Intelligence Solutions , ...
... European research initiative EUREKA will be represented with its ... of HANNOVER MESSE 2010 (19-23 April). This presentation underlines ... and Development in Hall 2. "We want ... central European platform with respect to the international networking ...
Cached Biology Technology:Moleac Announces Breakthrough Results on Neuroprotective and Neurogenerative Properties of NeuroAiD 2Moleac Announces Breakthrough Results on Neuroprotective and Neurogenerative Properties of NeuroAiD 3Lunch and Learn Workshop for New Jersey-based FDA-Regulated Companies 2European research initiative EUREKA presented at Research & Technology for the first time 2
... CAST Equine EIA Principle: ... LTD4 and LTE4 are products ... 5-lipoxygenase and glutathione-S-transferase. In the ... "Slow Reacting Substances of Anaphylaxis ...
... Compound(s) tested through 63 ... assays spanning a broad ... panel includes many non ... several non-selective assays. ...
... The Genome Sequencer 20 System revolutionizes ... massively parallel fashion. The Genome Sequencer ... accessories Reagents and consumables for library ... for mapping and de novo assembly ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
Biology Products: